Wire · opportunities
FDA Approves Camizestrant Plus CDK4/6 Inhibitor Following Emergence of ESR1 Mutation ...
◆ Sectors
◆ Geography
◆ Source
◆ Verified
Fusion42 · 9 September 2026 · Fusion42 review
The FDA granted accelerated approval to camizestrant combined with a CDK4/6 inhibitor for HR-positive, HER2-negative advanced breast cancer patients with ESR1 mutations detected during aromatase inhibitor and CDK4/6 inhibitor therapy, based on the phase 3 SERENA-6 trial showing significant progression-free survival benefit.
This Wire brief sits within Fusion42's coverage of Biotech, and 13 sources have reported it between 4 Sep 2026 and 8 Sep 2026.
◆ ◆ The Wire takeaway
You must adapt your HR-positive breast cancer treatments to integrate ESR1 mutation testing and camizestrant use now approved by the FDA. The biomarker-driven approach changes when you intervene before disease progression.
◆ Coverage
13 sources · first reported 4 Sep 2026 · latest 8 Sep 2026
◆ Topics